Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ocumension Therapeutics ( (HK:1477) ) has provided an update.
Ocumension Therapeutics has announced changes to its Nomination Committee in response to upcoming amendments to the Corporate Governance Code. Dr. Qin XIE and Mr. Ting Yuk Anthony WU have been appointed as new members, effective June 30, 2025, enhancing the committee’s composition with a blend of independent and non-executive directors.
The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
More about Ocumension Therapeutics
Average Trading Volume: 7,170,339
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.57B
Learn more about 1477 stock on TipRanks’ Stock Analysis page.